Figure 3. IFN-gamma CD8+ T cell responses to PARV4 peptides determined by ELISpot assays.

Data in ( A) and ( B) are derived by screening 14 subjects positive for PARV4 IgG recruited from the Kimberley (n=7, children) and Thames Valley (n=7, adults) cohorts. None of these subjects was PCR positive for PARV4 from serum. Raw data showing the responses made by each individual subject can be viewed in Supplementary data 4. ( A) Proportion of 14 screened subjects who made each individual response. ( B) Mean magnitude (box) and range of response (whiskers); the dashed horizontal line allows visualization of peptides for which the mean response is >1000 SFCs/10 ⁶ PBMC. Responses to NS peptides are shown in grey, to VP peptides in black, and to ARF in hatched bars. ( C) Prediction of a novel HLA-B*5703-restricted CD8+ T cell epitope in PARV4 NS protein. Cryopreserved PBMCs from PARV4 IgG-positive adult subject N087 (HIV-positive adult recruited via the Thames Valley cohort, HLA class I genotype HLA-A*0301/-A*3001/-B*5703/-B*5801/-C*0602/-C*1801) were screened by IFN-gamma ELISpot for responses to peptide truncations from PARV4 NS protein (sequences within OLPs 9.6 and 9.7) at different concentrations. Plots and error bars show mean and SEM of assays performed in triplicate. On the basis of the HLA-B*5703 binding motif and the greatest magnitude responses, the putative optimal epitope is HLA-B*5703-QF9 (QTRITMFQF).